Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib

J Gastrointest Cancer. 2023 Sep;54(3):982-985. doi: 10.1007/s12029-022-00852-w. Epub 2022 Aug 8.

Authors

Maishara Muquith¹, Magdalena Espinoza², David Hsiehchen³

Affiliations

¹ University of Texas Southwestern Medical School, Dallas, TX, 75390, USA.
² Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
³ Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. gbtwnow@gmail.com.

PMID: 35939228
DOI: 10.1007/s12029-022-00852-w

No abstract available

Keywords: Hepatic decompensation; Lenvatinib; Reversal.

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Phenylurea Compounds / adverse effects
Quinolines* / adverse effects

Substances

lenvatinib
Phenylurea Compounds
Quinolines